Key points are not available for this paper at this time.
Background: Physical activity benefits people with type 1 diabetes (PwT1D); however, PwT1D appear less active than their nondiabetic peers. This study seeks to investigate the potential of diabetes technologies in mitigating perceived barriers to physical activity in type 1 diabetes (T1D). Methods: A cross-sectional study with participants from the BETTER registry (age 14 years) who completed BAPAD-1 (Barriers to Physical Activity in T1D) questionnaire. A significant barrier is defined by score 5 to BAPAD-1 items. Four groups were defined according to the participants' treatment and blood glucose monitoring mode: Multiple daily injections (MDI) without continuous glucose monitoring (CGM), MDI with CGM, pump with CGM, and those using an automated insulin delivery system (AID). Results: Among 1019 eligible participants, the main perceived barrier is the fear of hypoglycemia. The mean BAPAD-1 score is similar for all groups. A higher proportion of individuals using AID systems reported significant barriers for items fear of hypoglycemia and loss of control over their diabetes compared to the No-CGM-MDI (+20% both), CGM-MDI (+7% and +10%), and CGM+Pump (+9% and +7%). Conclusion: Barriers to physical activity for PwT1D are not reduced by diabetes technologies. Some barriers are even perceived as more important for people using CGM, pump, and AID systems. Disclosure C. Guédet: None. S. Tagougui: None. V. Messier: None. V. Boudreau: None. A. Brazeau: Other Relationship; Dexcom, Inc. Research Support; Canadian Institutes of Health Research, Juvenile Diabetes Research Foundation (JDRF), Diabète québec, Fonds de recherche du Québec en Santé. R.P.R. Rabasa-Lhoret: Other Relationship; Abbott, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Dexcom, Inc. Research Support; Diabetes Canada. Other Relationship; Eli Lilly and Company. Research Support; Cystic Fibrosis Canada, Canadian Institutes of Health Research, FFRD - Fondation Francophone pour la Recherche du Diabète. Other Relationship; Janssen Pharmaceuticals, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Other Relationship; Novo Nordisk, GlaxoSmithKline plc. Consultant; HLS Therapeutics Inc., Insulet Corporation. Speaker's Bureau; CPD Networks. Other Relationship; Medtronic. Consultant; Pfizer Inc. Speaker's Bureau; Tandem Diabetes Care, Inc. Other Relationship; Sanofi. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; SFD - Société Francophone du Diabète.
Guédet et al. (Fri,) studied this question.